US2021060066A1PendingUtilityA1
Compositions and methods for platelet enriched fibrin constructs
Est. expirySep 30, 2031(~5.2 yrs left)· nominal 20-yr term from priority
Inventors:Mehmet Ziya SengunWilliam R. ParrishGregory R. WhittakerDouglas Allen FifoltBrooks J. Story
A61K 35/17A61L 15/32A61L 27/225A61L 27/38A61K 38/1875A61L 2300/414A61K 38/1825A61L 27/54A61K 38/1808A61K 38/1866A61K 38/363A61K 38/1841A61K 35/14A61P 43/00A61K 38/18A61K 38/55A61K 35/19
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compositions and methods are provided for tissue constructs that promote wound healing. The composition comprises a dimensionally stable fibrin construct for local administration to a wound site or region. In one embodiment, the fibrin construct is a wound healing composition, including components that promote wound healing, such as platelets, growth factors, white blood cells and fibrin clots. In another embodiment, the tissue treatment composition includes (i) aggregated fibrin, (ii) blood cells, and (iii) optionally, growth factors and/or other proteins.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 - 20 . (canceled)
21 . A bioimplantable construct, comprising:
a fibrin construct derived from whole blood, having a growth factor enriched surface concentrated with blood cells and platelets capable of releasing a growth factor and a growth factor depleted surface, the fibrin construct being dimensionally stable and suturable.
22 . The construct of claim 21 , wherein the growth factor depleted surface is substantially lacking in blood cells.
23 . The construct of claim 21 , wherein the growth factor depleted surface is substantially lacking in red blood cells.
24 . The construct of claim 21 , wherein the growth factor depleted surface includes white blood cells.
25 . The construct of claim 21 , wherein the fibrin construct has a resiliency that is defined by an elongation at break strength of at least about 200%.
26 . The construct of claim 21 , wherein the fibrin construct has a strength that is defined by an ultimate strength of at least about 0.15 MPa.
27 . The construct of claim 21 , wherein the fibrin construct has a strength that is defined by a compression strength of at least about 30 kPa
28 . The construct of claim 21 , wherein the fibrin construct is a folded construct that is folded upon itself so that adjacent halves of the growth factor enriched surface contact each other and form an inner portion of the folded construct while the growth factor depleted surface forms an outer portion of the folded construct.
29 . The construct of claim 28 , wherein the folded construct is sutured along at least one edge thereof to secure the folded construct in the folded condition.
30 . The construct of claim 21 , wherein the fibrin construct is in the form of a multilayered construct in which two fibrin constructs are joined together with the growth factor enriched surfaces facing each other form an inner portion of the multilayered construct and the growth factor depleted surfaces form an outer portion of the multilayered construct.
31 . The construct of claim 30 , wherein the multilayered construct includes sutures extending between the adjacent constructs along at least a portion of an edge thereof to secure the multilayered construct.
32 - 51 . (canceled)Join the waitlist — get patent alerts
Track US2021060066A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.